Ixchiq HCP

Références

  1. Monographie d’IXCHIQMC. 20 juin 2024.
  2. Données internes sur IXCHIQMC. 2024.
  3. Organisation mondiale de la Santé. Chikungunya. Publié le 8 décembre 2022. Consulté le 13 mars 2024. Disponible au : https://www.who.int/fr/news-room/fact-sheets/detail/chikungunya.
  4. Craig J, et al. Diagnostic challenges in chikungunya infection. 2015;41(1):6-10.
  5. Organisation mondiale de la Santé. Chikungunya Overview. Consulté le 18 juillet 2024. Disponible au : https://www.who.int/health-topics/chikungunya#tab=tab_1.
  6. Thiberville, SD, et al. Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy. Antivir Res. 2013;99(3):345-370.
  7. Sahadeo N, et al. Molecular characterisation of chikungunya virus infections in Trinidad and comparison of clinical and laboratory features with dengue and other acute febrile cases. PLoS Negl Trop Dis. 2015;9(11):e0004199.
  8. Puntasecca CJ, King CH, LaBeaud AD. Measuring the global burden of chikungunya and Zika viruses: A systematic review. PLoS Negl Trop Dis. 2021;15(3):e0009055.
  9. Centers for Disease Control and Prevention. Areas at risk for chikungunya. Mis à jour le 19 juillet 2024. Consulté le 6 mars 2024. Disponible au : https://www.cdc.gov/chikungunya/data-maps/index.html#:~:text=Chikungunya%20virus%20circulates%20in%20tropical,the%20Indian%20and%20Pacific%20Oceans.
  10. de Souza, et al. Pathophysiology of chikungunya virus infection associated with fatal outcomes. Cell Host Microbe. 2024;32:606–622.
  11. European Centre for Disease Prevention and Control. Chikungunya worldwide overview. 8 mai 2024. Disponible au : https://www.ecdc.europa.eu/en/chikungunya-monthly.
  12. Boggild AK. et al. Chikungunya in travellers returning to Canada: Surveillance report from CanTravNet surveillance data, 2006 to 2015. J Assoc Med Microbiol Infect Dis Can. 2016;1(3):1-16.
  13. Suhrbier A. Rheumatic manifestations of chikungunya: emerging concepts and interventions. Nat Rev. 2019;15:597-611.
  14. Centers for Disease Control and Prevention. Chikungunya in Maldives. Consulté le 19 juillet 2024. Disponible au : https://wwwnc.cdc.gov/travel/notices/level2/chikungunya-maldives#:~:text=Vaccination%20for%20chikungunya%20is%20recommended,close%20to%20delivering%20your%20baby.
  15. Staples JE, Hills S, Powers A. Chapter 4: Chikungunya/ Dans : Nemhauser J, ed. CDC Yellow Book 2024. Centers for Disease Control and Prevention. Consulté le 13 mars 2024. Disponible au : https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/chikungunya.
  16. Bettis AA, et al. The global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the development and introduction of vaccines. PLoS Negl Trop Dis. 2022 6(1): e0010069.
  17. Nemg Simo FB, et al. Chikungunya virus diagnosis: A review of current antigen detection methods. Trop Med Infect Dis. 2023;8(7):365.
  18. Pathak H, et al. Chikungunya arthritis. Clin Med. 2019;19(5):381–385.
  19. Silva L, Dermody T. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest. 2017;127(3):737-749.
  20. Paixão ES, et al. Chikungunya chronic disease: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg. 2018;1123(7):301-316.
  21. Marques CDL, et al. Recommendations of the Brazilian Society of Rheumatology for diagnosis and treatment of Chikungunya fever. Part 1 – Diagnosis and special situations. Rev Bras Reumatol. 2017;57(S2):S421-S437.
  22. Essackjee K, et al. Prevalence of and risk factors for chronic arthralgia and rheumatoid-like polyarthritis more than 2 years after infection with chikungunya virus. Postgrad Med J. 2013;89(1054):440-447.
  23. Organisation mondiale de la Santé. Guidelines on Clinical Management of Chikungunya Fever. Publié en octobre 2008. Consulté le 25 juillet 2024. Disponible au : https://iris.who.int/bitstream/handle/10665/205178/B3234.pdf?sequence=1.
  24. Schneider, M., et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet. 2023;401:2138–2147.
  25. Centers for Disease Control and Prevention. ACIP Recommendations. Mis à jour le 6 mars 2024. Consulté le 18 avril 2024. Disponible au : https://www.cdc.gov/vaccines/acip/recommendations.html.
  26. Centers for Disease Control and Prevention. Factors to assess when considering use of chikungunya vaccine. Mis à jour le 15 mai 2024. Consulté le 19 juillet 2024. Disponible au : https://www.cdc.gov/chikungunya/media/pdfs/2024/05/Chikungunya-vaccine-risk-factors-508.pdf.
Valneva Canada Inc.
Commercial Operations
3535 Saint-Charles Blvd., Suite 600
Kirkland (Québec) H9H 5B9, Canada
Telephone: 514-630-6999
Valneva Canada Inc. 
Affaires commerciales
3535, boul. Saint-Charles, bureau 600
Kirkland (Québec) H9H 5B9 Canada
Téléphone : 514-630-6999
This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.